$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

Recently, the rearrangement of RET proto-oncogene has been reported to be the most common genetic change in papillary thyroid carcinoma (PTC). However, its prevalence has been reported variably and its relation to clinical outcome has been controversial. The characteristic nuclear features of PTC usually render the diagnosis, but problem arises with equivocal cytologic features that are present focally. Although there remains some controversy, CK19 has been reported to be a useful ancillary tool for diagnosis of PTC. To evaluate the expression rate of RET/PTC rearrangement and CK19 in PTCs in a Korean population, we studied 115 papillary thyroid carcinomas in 3 mm-core tissue microarray based immunohistochemical analysis. The prevalence of Ret protein expression was 62.6% and the CK19 immunoreactivity was 80.9%. There was no statistically significant association between the Ret positivity and CK19 immunoreactivity, although the percent agreement of the two was relatively high. The clinicopathological variables did not correlate with the expression of Ret. In conclusion, the prevalence of Ret protein expression and its clinicopathological implications in a Korean population are not much different from those reported in previous studies. However, its detection via immunohistochemistry can be a useful diagnostic tool for diagnosing papillary thyroid carcinoma in conjunction with CK19.

참고문헌 (33)

  1. 1. 1 Rosai J Carcangiu ML DeLellis RA Tumors of the thyroid gland. Atlas of Tumor Pathology, Third Series, Fascicle 5 1992 Washington, DC Armed Forces Institute of Pathology 65 121 
  2. 2. 2 Kjellman P Learoyd DL Messina M Weber G Hoog A Wallin G Larson C Robinson BG Zedenius J Expression of the RET protooncogene in papillary thyroid carcinoma and its correlation with clinical outcome Br J Surg 2001 88 557 563 11298625 
  3. 3. 3 Belfiore A Gangemi P Costantino A Russo G Santonocito G Ippolito O DiRenzo MF Comoglio P Fiumara A Vigneri R Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases J Clin Endocrinol Metab 1997 82 2322 2328 9215314 
  4. 4. 4 Basolo F Molinaro E Agate L Pinchera A Pollina L Chiappetta G Monaco C Santoro M Fusco A Miccoli P Elisei R Capezzone M Pacini F RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma Eur J Endocrinol 2001 145 599 604 11720878 
  5. 5. 5 Pierotti MA Bongarzone I Borrello MG Greco A Pilotti S Sozzi G Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells Genes Chromosomes Cancer 1996 16 1 14 9162191 
  6. 6. 6 Santoro M Carlomagno F Hay ID Hermann MA Grieco M Melillo R Pierotti MA Bongarzone I Della Porta G Berger N Ret oncogene activation in thyroid neoplasms is restricted to the papillary cancer subtype J Clin Invest 1992 89 1517 1522 1569189 
  7. 7. 7 Grieco M Santoro M Berlingieri MT Melillo RM Donghi R Bongarzone I Pierotti MA Della Porta G Fusco A Vecchio G PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 1990 60 557 563 2406025 
  8. 8. 8 Pierotti MA Santoro M Jenkins RB Sozzi G Bongarzone I Grieco M Monzini N Miozzo M Herrmann MA Fusco A Hay ID Della Porta G Vecchio G Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC Proc Natl Acad Sci USA 1992 89 1616 1620 1542652 
  9. 9. 9 Lee CH Hsu LS Chi CW Chen GD Yang AH Chen JY High frequency of rearrangement of the RET proto-oncogene (RET/PTC) in Chinese papillary thyroid carcinomas J Clin Endocrinol Metab 1998 83 1629 1632 9589668 
  10. 10. 10 Wajjwalku W Nakamura S Hasegawa Y Miyazaki K Satoh Y Funahashi H Matsuyama M Takahashi M Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas Jpn J Cancer Res 1992 83 671 675 1381340 
  11. 11. 11 Jhiang SM Caruso DR Gilmore E Ishizaka Y Tahira T Nagao M Chiu IM Mazzaferri EL Detection of the PTC/retTPC oncogene in human thyroid cancers Oncogene 1992 7 1331 1337 1620547 
  12. 12. 12 Zou M Shi Y Farid NR Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia Cancer 1994 73 176 180 8275421 
  13. 13. 13 Viglietto G Chiappetta G Martinez-Tello FJ Fukunaga FH Tallini G Rigopoulou D Visconti R Mastro A Santoro M Fusco A RET/PTC oncogene activation is an early event in thyroid carcinogenesis Oncogene 1995 11 1207 1210 7566982 
  14. 14. 14 Sugg SL Zheng L Rosen IB Freeman JL Ezzat S Asa SL ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 1996 81 3360 3365 8784097 
  15. 15. 15 Miki H Kitaichi M Masuda E Komaki K Yamamoto Y Monden Y ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma J Surg Oncol 1999 71 76 81 10389862 
  16. 16. 16 Raphael SJ McKeown-Eyssen G Asa SL High-molecular weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors Mod Pathol 1994 7 295 300 7520169 
  17. 17. 17 Schelfhout LJ Van Muijen GN Fleuren GJ Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma Am J Clin Pathol 1989 92 654 658 2479256 
  18. 18. 18 Beesley MF McLaren KM Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules Histopathology 2002 41 236 243 12207785 
  19. 19. 19 Sahoo S Hoda SA Rosai J DeLellis RA Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution Am J Clin Pathol 2001 116 696 702 11710686 
  20. 20. 20 Miettinen M Kovatich AJ Karkkainene P Keratin subsets in papillary and follicular thyroid lesion: a paraffin section analysis with diagnostic implications Virchows Arch 1997 431 407 413 9428928 
  21. 21. 21 Baloch ZW Abraham S Roberts S LiVolsi VA Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility Hum Pathol 1999 30 1166 1171 10534163 
  22. 22. 22 Komminoth P The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications Virchows Arch 1997 431 1 9 9247627 
  23. 23. 23 Fischer AH Bond JA Taysavang P Battles OE Wynford-Thomas D Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure Am J Pathol 1998 153 1443 1450 9811335 
  24. 24. 24 Motomura T Nikiforov YE Namba H Ashizawa K Nagataki S Yamashita S Fagin JA RET rearrangements in Japanese pediatric and adult papillary thyroid cancers Thyroid 1998 8 485 489 9669285 
  25. 25. 25 Park KY Koh JM Kim YI Park HJ Gong G Hong SJ Ahn IM Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumors in a Korean population Clin Endocrinol 1998 49 317 323 
  26. 26. 26 Chung JH Hahm JR Min YK Lee MS Lee MK Kim KW Nam SJ Yang JH Ree HJ Detection of RET/PTC oncogene rearrangements in Korean papillary thyroid carcinomas Thyroid 1999 9 1237 1243 10646664 
  27. 27. 27 Chung KW Chang MC Noh DY Oh SK Choe KJ Youn YK RET oncogene expression of papillary thyroid carcinoma in Korea Surg Today 2004 34 485 492 15170542 
  28. 28. 28 Cheung CC Ezzat S Freeman JL Rosen IB Asa SL Immunohistochemical diagnosis of papillary thyroid carcinoma Mod Pathol 2001 14 338 342 11301350 
  29. 29. 29 Hoos A Urist MJ Stojadinovic A Mastorides S Dudas M Kuo D Brennan MF Lewis JJ Cordon-Cardo C Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors Am J Pathol 2001 158 1245 1251 11290542 
  30. 30. 30 Chiappetta G Hui P Santoro M RET/PTC oncogene activation and assessment of clonality in thyroid nodules with minimal cytologic evidence of papillary carcinoma Lab Invest 2001 81 75A 
  31. 31. 31 Soares P Fonseca E Wynford-Thomas D Sobrinho-Simoes M Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 1998 185 71 78 9713362 
  32. 32. 32 Tallini G Santoro M Helie M Carlomagno F Salvatore G Chiappetta G Carcangiu ML Fusco A RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes Clin Cancer Res 1998 4 287 294 9516913 
  33. 33. 33 Mayr B Goretzki P Ruschoff J Dralle H Ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential [Letter]? J Clin Endocrinol Metab 1997 82 1306 1307 9100614 

원문보기

원문 PDF 다운로드

  • 원문 PDF 정보가 존재하지 않습니다.

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

DOI 인용 스타일

"" 핵심어 질의응답